Pre-Op Hydronephrosis Predicts Outcomes in Patients Receiving Robot-Assisted Radical Cystectomy

Chris Ho-Ming Wong, Ivan Ching‐Ho Ko, David Leung, Seok Ho Kang, K. Kitamura, Shigeo Horie, Satoru Muto, Chikara Οhyama, Shingo Hatakeyama, Manish I. Patel, Cheung-Kuang Yang, Kittinut Kijvikai, Ji Youl Lee, Haige Chen, Ruiyun Zhang, Tianxin Lin, Lui Shiong Lee, Jeremy Yuen‐Chun Teoh, Eddie ChanCancers 2024 · DOI

TL;DR

This study reveals that a common condition called hydronephrosis (swelling of the kidney due to urine blockage), often seen in advanced bladder cancer, is a significant predictor of worse outcomes after robot-assisted radical cystectomy (RARC). Patients with pre-operative hydronephrosis experienced more complications, higher rates of pathological upstaging, and notably, poorer long-term survival rates, even when accounting for tumor stage.

What Problem Does This Paper Address?

Muscle-invasive bladder cancer (MIBC) is a serious condition often treated with radical cystectomy (bladder removal). Robot-assisted radical cystectomy (RARC) has become a popular, minimally invasive alternative to open surgery, offering proven oncological benefits. However, identifying factors that predict patient outcomes after RARC is crucial for better patient selection, counseling, and treatment planning. Hydronephrosis, a sign of urinary tract obstruction, is frequently observed in advanced bladder cancer. While its prognostic significance has been explored in open surgery, its specific impact on outcomes following RARC, especially in diverse Asian populations, remained less clear. This paper aims to fill that gap by investigating how pre-operative hydronephrosis affects perioperative, pathological, and survival outcomes in patients undergoing RARC.

Methods

This study employed a retrospective, multicenter design, analyzing data from the Asian RARC Consortium, which comprises nine high-volume centers across Asia. Patients undergoing RARC for non-metastatic MIBC between 2007 and 2020 were included. The primary exposure variable was the presence or absence of pre-operative hydronephrosis, identified through the most recent cross-sectional imaging (CT or MRI).

The study collected data on patient demographics, disease characteristics (including pathological T and N staging), operative details (console time, blood loss, urinary diversion type), and perioperative outcomes (hospital stay, complications graded by Clavien-Dindo classification, 30-day readmissions). Long-term outcomes focused on disease-free survival (DFS) and overall survival (OS).

Statistical analysis involved descriptive statistics for patient characteristics. Categorical variables were compared using Chi-square tests, and continuous variables using Student's T-tests. Crucially, multivariate Cox regression analyses were performed to identify independent predictors of DFS and OS, adjusting for potential confounders such as tumor stage, surgical margins, and adjuvant therapy. Subgroup analyses were conducted based on pathological T stage (pT2+ and pT3+ subgroups) to further scrutinize the impact of hydronephrosis in conjunction with tumor severity.

Datasets

The study utilized a dataset from the Asian RARC Consortium, a multicenter registry. This dataset included data from 536 patients who underwent RARC between 2007 and 2020 across nine Asian centers. 20 cases were excluded due to missing baseline data. The dataset is characterized by its real-world, multicenter nature, offering a broad perspective on RARC outcomes in an Asian population. No new benchmarks were introduced; rather, existing patient data was analyzed.

Key Insights and Ideas

  • Hydronephrosis as a "Red Flag": The study strongly suggests that pre-operative hydronephrosis is more than just a symptom of advanced cancer; it's an independent prognostic indicator of worse outcomes after RARC. This implies that its presence should prompt closer scrutiny and potentially influence treatment decisions.
  • Beyond Tumor Stage: While tumor stage is a known predictor, hydronephrosis appears to add significant prognostic value on top of tumor staging. This means patients with hydronephrosis might face worse outcomes even if their tumor stage appears similar to patients without it.
  • Potential Mechanisms: The paper speculates on why hydronephrosis might lead to poorer outcomes. Theories include:
  • Increased CTC Dissemination: Chronic obstruction could lead to higher hydrostatic pressure, potentially facilitating the release of circulating tumor cells (CTCs) into the bloodstream, which are known to correlate with worse survival.
  • Lymph Node Metastasis: The chronicity associated with hydronephrosis might increase the likelihood of micrometastases in lymph nodes, a factor that can be difficult to detect but significantly impacts prognosis.
  • Tumor Spillage Risk: Hydronephrotic ureters might present technical challenges during surgery, potentially increasing the risk of tumor spillage, which is linked to recurrence.

Key Results

  • Prevalence: Out of 536 patients, 107 (20.0%) had pre-operative hydronephrosis.
  • Complications: Patients with hydronephrosis had a significantly higher risk of pathological upstaging (41.1% vs. 29.1%), 30-day readmission (40.2% vs. 20.5%), and severe post-operative complications (Clavien-Dindo grade ≥ 3) (24.3% vs. 13.3%).
  • Survival Outcomes:
    • Overall Cohort: Hydronephrosis was a significant predictor of inferior 10-year disease-free survival (DFS) (HR = 1.701) and overall survival (OS) (HR = 1.834).
  • Subgroup Analysis: This association persisted in advanced disease subgroups:
  • pT2+ subgroup: Hydronephrosis predicted worse DFS (HR = 1.753) and OS (HR = 1.888).
  • pT3+ subgroup: Hydronephrosis predicted worse DFS (HR = 1.757) and OS (HR = 1.807).
  • Multivariate Analysis: After adjusting for confounders, hydronephrosis remained an independent predictor of worse DFS and OS across the entire cohort and in the advanced disease subgroups.

Limitations and Future Work

The authors acknowledge several limitations:

  • Retrospective Nature: This inherent limitation means potential unidentified confounders and selection bias cannot be entirely ruled out.
  • Follow-up Duration: While the study aimed for long-term follow-up, the interpretation of results might be influenced by varying adoption rates of robotic surgery across centers, leading to a later time point for many RARC cases.
  • Western vs. Asian Data: Most existing RARC literature is from Western populations. While this study uses Asian data, direct comparisons of ethnic differences and treatment outcomes are not fully assessed.
  • Bilateral Hydronephrosis: The limited number of patients with bilateral hydronephrosis precluded specific subgroup analysis for this condition.

Future work could focus on prospective studies to confirm these findings and further elucidate the biological mechanisms linking hydronephrosis to poorer oncological outcomes. Investigating the role of circulating tumor cells (CTCs) and the impact of intraoperative techniques to minimize tumor spillage in hydronephrotic patients would be valuable. The authors emphasize that preoperative hydronephrosis should be a key consideration in patient selection and management strategies for RARC.

Summary updated

Abstract

The presence of preoperative hydronephrosis among MIBC patients carries additional prognostic implications on top of tumour staging. Its importance in case selection needs to be highlighted.
BibTeX
@inproceedings{wong2024pre,
  author = {Chris Ho-Ming Wong and Ivan Ching‐Ho Ko and David Leung and Seok Ho Kang and K. Kitamura and Shigeo Horie and Satoru Muto and Chikara Οhyama and Shingo Hatakeyama and Manish I. Patel and Cheung-Kuang Yang and Kittinut Kijvikai and Ji Youl Lee and Haige Chen and Ruiyun Zhang and Tianxin Lin and Lui Shiong Lee and Jeremy Yuen‐Chun Teoh and Eddie Chan},
  title = {{Pre-Op Hydronephrosis Predicts Outcomes in Patients Receiving Robot-Assisted Radical Cystectomy}},
  booktitle = {Cancers},
  year = {2024},
  doi = {10.3390/cancers16162826},
}
Figure